• ProKidney will present pooled Phase 2 rilparencel results at the American Society of Nephrology’s Kidney Week on October 23, 2026.
• The analysis indicated a strong safety profile with kidney function stabilization in patients with advanced chronic kidney disease and type 2 diabetes.
• Participants met key eligibility criteria for the ongoing Phase 3 PROACT 1 trial.
• Seven additional abstracts will present nonclinical evidence supporting rilparencel’s multifactorial mechanism of action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220800PRIMZONEFULLFEED9850493) on October 22, 2026, and is solely responsible for the information contained therein.